Zealand Pharma A/S

Research Zealand Pharma A/S (ZEAL) on Bullrun: valuation model: 133.0% undervalued, market cap DKK 19.93B, P/E 3.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerZEAL
• ExchangeCO
• CountryDenmark
• SectorHealthcare
• IndustryBiotechnology
• CurrencyDKK
• Valuation signal133.0% undervalued
• Market capDKK 19.93B
• P/E3.2
• Financial periodQ4 2025
• RevenueDKK 68.92M
• Net income-DKK 379.12M
• Free cash flow-DKK 1.09B
• Gross margin100.0%

Valuation Snapshot

Bullrun's latest valuation model marks Zealand Pharma A/S as 133.0% undervalued; latest market cap is DKK 19.93B; P/E is 3.2.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

Frequently asked questions

Is Zealand Pharma A/S overvalued or undervalued?

Bullrun's valuation model currently marks Zealand Pharma A/S as 133.0% undervalued.

What is Zealand Pharma A/S's market cap?

Zealand Pharma A/S's market capitalization is DKK 19.93B.

What is Zealand Pharma A/S's P/E ratio?

Zealand Pharma A/S's price-to-earnings (P/E) ratio is 3.2.

What does Zealand Pharma A/S do?

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.